Program Urges Increased Cancer Data Sharing
Stakeholders of Project Data Sphere authored a Sounding Board article in the New England Journal of Medicine urging the responsible sharing of cancer trial data with global researchers.
In an example of the continued push among industry, academia, government, and hospitals to share more clinical research data, stakeholders of Project Data Sphere, LLC (PDS), a non-profit initiative of the CEO Roundtable on Cancer's Life Sciences Consortium, authored a Sounding Board article in this week’s New England Journal of Medicine urging the responsible sharing of cancer trial data with global researchers. Allowing researchers direct data access, the authors say, is critical to eliminating siloes and expanding discoveries and learnings in oncology R&D for the benefit of patients.
To that end, PDS has its own open-access cancer data platform, housing a free digital library of data. The platform, launched in 2014, allows researchers to download, share, integrate, and analyze patient data, while keeping patient anonymity intact. Presently, the platform includes 72 datasets resulting from nearly 42,000 patient lives, and PDS intends to expand the data and optimize the sharing of learned resources for trial participants. The platform can be found here: www.ProjectDataSphere.org
The CEO Roundtable on Cancer, comprised of top leaders from more than 30 U.S. companies, was founded by President Bush in 2001.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Optimizing Phase III Oncology Trial Recruitment with Data-Driven Insights
February 3rd 2025A pharmaceutical company aimed to launch a Phase III clinical trial for a new oncology drug, focusing on efficient and effective patient recruitment across diverse regions. They evaluated patient populations by analyzing demographics, social determinants of health, and geography. Investigator profiling included practice details, affiliations, referral networks, and clinical trial experience. The final step involved selecting and extracting target lists for implementation.
